Conversation has moved to delivery: the call's center of gravity is how and when real business converts, not whether it
The model's full reasoning — Q4 2023 call → NOWe need to evaluate the transcript against the criteria. The call is about CollPlant Biotechnologies, a regenerative medicine company. Key programs: dermal filler partnered with AbbVie (in clinical phase), regenerative breast implants (in large animal studies), and a gut-on-a-chip program (put on hold). Also collaborations with Stratasys for bioprinting. The question: Has the center of gravity moved past whether demand exists, onto practical mechanics of converting real business into delivered results? Check (1) Business already real? The dermal filler with AbbVie is in clinical phase, and they received a $10M milestone payment. That is real, ongoing collaboration. The breast implants are in large animal studies, not yet commercial. The gut-on-a-chip is on hold. So the most concrete real business is the AbbVie collaboration, which is in clinical trials. But is that "orders, contracts, customers, programs, volumes, openings, deployments, or work that has already been won, begun, or committed"? Yes, it's a contract with milestones. However, the discussion on the call is largely about development progress, not about converting existing demand into delivered results. The breast implants are still in animal studies, not yet commercial. The call also discusses market opportunities (e.g., breast implant market size, biofabrication market). Analysts ask about timing of data from animal studies, and about milestone payments. But the overall conversation is more about development pipeline and future potential, not about converting existing real business into delivered results. The company is pre-revenue except for some collagen sales and milestone payments. The main focus is on advancing clinical programs. The analysts' questions are about timing of data and milestones, not about ramping up production or delivery. Management talks about ongoing studies and collaborations, but the business is still in development stage. The criteria require that the business is already real and the dialogue dwells on conversion mechanics. Here, the business is largely prospective (breast implants not yet commercial, dermal filler in clinical trials). The call is more about progress and future plans. So answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ERO | Ero Copper Corp. | Q1 2024 | 2024-05-10 | A |
| LINC | Lincoln Educational Services Corporation | Q1 2024 | 2024-05-06 | B+ |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| BRBR | BellRing Brands, Inc. | Q4 2023 | 2023-11-21 | B+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| GOLD | Barrick Gold Corporation | Q3 2023 | 2023-11-02 | C |
| CMG | Chipotle Mexican Grill, Inc. | Q3 2023 | 2023-10-27 | B+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| PTLO | Portillo's Inc. | Q2 2023 | 2023-08-05 | B |
| AFL | Aflac Incorporated | Q2 2023 | 2023-08-02 | C+ |
| CTO | CTO Realty Growth, Inc. | Q2 2023 | 2023-07-28 | B |
| CDE | Coeur Mining, Inc. | Q1 2023 | 2023-05-11 | C+ |
| SU | Suncor Energy Inc. | Q1 2023 | 2023-05-09 | C+ |
| ULCC | Frontier Group Holdings, Inc. | Q1 2023 | 2023-05-07 | C+ |
| SBRA | Sabra Health Care REIT, Inc. | Q1 2023 | 2023-05-04 | B |
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| UAL | United Airlines Holdings, Inc. | Q4 2022 | 2023-01-18 | B |
| PKOH | Park-Ohio Holdings Corp. | Q3 2022 | 2022-11-13 | B |
| CHE | Chemed Corporation | Q3 2022 | 2022-11-01 | B+ |
| TMCI | Treace Medical Concepts, Inc. | Q2 2022 | 2022-08-13 | B+ |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| HLIO | Helios Technologies, Inc. | Q1 2022 | 2022-05-10 | C |
| BFIN | BankFinancial Corporation | Q1 2022 | 2022-05-06 | A |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| HY | Hyster-Yale Materials Handling, Inc. | Q3 2021 | 2021-11-06 | D |
| KTB | Kontoor Brands, Inc. | Q3 2021 | 2021-11-04 | A |
| LMAT | LeMaitre Vascular, Inc. | Q3 2021 | 2021-10-29 | C+ |
| FFWM | First Foundation Inc. | Q3 2021 | 2021-10-26 | B |
| EGY | VAALCO Energy, Inc. | Q2 2021 | 2021-08-12 | B |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| EMR | Emerson Electric Co. | Q3 2021 | 2021-08-04 | B+ |
| EHTH | eHealth, Inc. | Q2 2021 | 2021-07-29 | F |
| ALB | Albemarle Corporation | Q3 2018 | 2018-11-08 | B |
| WES | Western Midstream Partners, LP | Q3 2018 | 2018-10-31 | D |
| AU | AngloGold Ashanti's | Q2 2018 | 2018-08-20 | B |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| KIM | Kimco Realty Corporation | Q2 2018 | 2018-07-26 | B+ |
| JBT | John Bean Technologies Corporation | Q2 2018 | 2018-07-26 | B |
| CP | Canadian Pacific Railway Limited | Q2 2018 | 2018-07-19 | B+ |
| MKC | McCormick & Company, Incorporated | Q2 2018 | 2018-06-28 | C+ |
| FSS | Federal Signal Corporation | Q1 2018 | 2018-05-12 | A |
| EPAM | EPAM Systems, Inc. | Q4 2017 | 2018-02-16 | B |
| AOSL | Alpha and Omega Semiconductor Limited | Q2 2018 | 2018-02-07 | B |
| CPK | Chesapeake Utilities Corporation | Q3 2017 | 2017-11-10 | A |
| RACE | Ferrari N.V. | Q3 2017 | 2017-11-02 | C+ |
| ABM | ABM Industries Incorporated | Q2 2017 | 2017-06-08 | B |
| FIX | Comfort Systems USA, Inc. | Q1 2017 | 2017-04-30 | A |
| GPOR | Gulfport Energy Corporation | Q4 2016 | 2017-02-14 | A |
| ARAY | Accuray Incorporated | Q4 2016 | 2016-08-17 | B |
| LBTYK | Liberty Global's | Q1 2016 | 2016-05-10 | C+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
GOLD · Q3 2023 → YESThe question is: Has the center of gravity of the discussion moved past whether demand exists, onto the practical mechanics of converting already real business into delivered results? YES The transcript shows the center of gravity has shifted to execution mechanics for already-committed operations and growth projects. Management details current production (up QoQ at NGM, Loulo-Gounkoto, Kibali), specific ramp-up challenges and fixes at Pueblo Viejo (gearbox failures, conveyor issues, temporary 70-75% throughput solutions, new assemblages arriving end-2023), tailings permitting, and phased construction at RekoDiq/Lumwana (2025 start, 2028/2026 first production). Analysts press on Q4 production, 2024 profiles (PV >800koz despite delays), recovery rates 70% to design, capital sequencing ($2.5B 2024, peaks 2025-26), and conversion timing (downtimes, relocations, training).
LBTYK · Q1 2016 → YESThe question is: Has the center of gravity of the discussion moved past whether demand exists, onto the practical mechanics of converting already real business into delivered results? YES The call as a whole satisfies both conditions. Management repeatedly frames the business as already real—existing customer bases, price increases already implemented across two-thirds of the footprint, 210,000 new-build homes added in Q1, 330,000 premises released under Project Lightning, 100,000 postpaid mobile subs added organically, BASE integration underway, and the Cable & Wireless transaction closing next week.
DXCM · Q4 2023 → YESThe question is: has the CENTER OF GRAVITY of the discussion visibly moved PAST the question of whether demand for the company's offering exists, and ONTO the practical mechanics of converting busines...